TY - JOUR
T1 - Antihyperlipidemic effects of stilbenoids isolated from Morus alba in rats fed a high-cholesterol diet
AU - Jo, Sung Pil
AU - Kim, Jeong Keun
AU - Lim, Young Hee
N1 - Funding Information:
This work (Grant No. C0033118 ) was supported by the Business for Cooperative R&D between Industry, Academy, and Research Institute funded by the Korea Small and Medium Business Administration in 2012.
PY - 2014/3
Y1 - 2014/3
N2 - Mulberroside A (MUL) was purified from an ethanol extract of Morus alba root, and oxyresveratrol (OXY) was produced by enzymatic conversion of MUL. Normal rats, Triton WR-1339-induced hyperlipidemic rats, and high-cholesterol diet (HCD)-induced hyperlipidemic rats were orally treated with MUL or OXY (1-5. mg/kg/day). MUL and OXY were administered 1. h prior to concomitant treatment with Triton WR-1339 for a further 24. h, whereas the drugs were administered concurrently with HCD for 4. weeks. Oral MUL and OXY pre-treatment vs. water pre-treatment of Triton WR-1339-induced hyperlipidemic rats significantly (p<. 0.05) reduced the levels of serum lipids in a dose-dependent manner, while high-density lipoprotein cholesterol (HDL-C, or "good" cholesterol) levels were increased. Oral MUL and OXY treatment of HCD-fed rats also showed a significant (p<. 0.05) dose-dependent decrease in serum lipids, coronary artery risk index (CRI), and atherogenic index (AI), but not HDL-C. Furthermore, MUL and OXY treatment of HCD-induced hyperlipidemic rats demonstrated a significant dose-dependent improvement in the histological features of hepatic fatty degeneration. Aspartate aminotransferase and alanine aminotransferase values in OXY-treated normal rats were not significantly different from those in water-treated control rats. These results indicate that MUL and OXY might be developed as novel antihyperlipidemic agents.
AB - Mulberroside A (MUL) was purified from an ethanol extract of Morus alba root, and oxyresveratrol (OXY) was produced by enzymatic conversion of MUL. Normal rats, Triton WR-1339-induced hyperlipidemic rats, and high-cholesterol diet (HCD)-induced hyperlipidemic rats were orally treated with MUL or OXY (1-5. mg/kg/day). MUL and OXY were administered 1. h prior to concomitant treatment with Triton WR-1339 for a further 24. h, whereas the drugs were administered concurrently with HCD for 4. weeks. Oral MUL and OXY pre-treatment vs. water pre-treatment of Triton WR-1339-induced hyperlipidemic rats significantly (p<. 0.05) reduced the levels of serum lipids in a dose-dependent manner, while high-density lipoprotein cholesterol (HDL-C, or "good" cholesterol) levels were increased. Oral MUL and OXY treatment of HCD-fed rats also showed a significant (p<. 0.05) dose-dependent decrease in serum lipids, coronary artery risk index (CRI), and atherogenic index (AI), but not HDL-C. Furthermore, MUL and OXY treatment of HCD-induced hyperlipidemic rats demonstrated a significant dose-dependent improvement in the histological features of hepatic fatty degeneration. Aspartate aminotransferase and alanine aminotransferase values in OXY-treated normal rats were not significantly different from those in water-treated control rats. These results indicate that MUL and OXY might be developed as novel antihyperlipidemic agents.
KW - Antihyperlipidemic activity
KW - Atherogenic index
KW - High-cholesterol diet
KW - Stilbenoids
UR - http://www.scopus.com/inward/record.url?scp=84892889356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892889356&partnerID=8YFLogxK
U2 - 10.1016/j.fct.2013.12.040
DO - 10.1016/j.fct.2013.12.040
M3 - Article
C2 - 24407019
AN - SCOPUS:84892889356
SN - 0278-6915
VL - 65
SP - 213
EP - 218
JO - Food and Chemical Toxicology
JF - Food and Chemical Toxicology
ER -